NASDAQ:GTXI - GTX Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.9440 -0.02 (-2.07 %)
(As of 02/18/2019 02:00 AM ET)
Previous Close$0.9440
Today's Range$0.93 - $0.9749
52-Week Range$0.74 - $25.60
Volume527,471 shs
Average Volume262,313 shs
Market Capitalization$22.71 million
P/E Ratio-0.54
Dividend YieldN/A
Beta2.54
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

Receive GTXI News and Ratings via Email

Sign-up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GTXI
CUSIP40052B10
Phone901-523-9700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.78 per share

Profitability

Net Income$-30,430,000.00

Miscellaneous

Employees27
Market Cap$22.71 million
OptionableOptionable

GTX (NASDAQ:GTXI) Frequently Asked Questions

What is GTX's stock symbol?

GTX trades on the NASDAQ under the ticker symbol "GTXI."

How were GTX's earnings last quarter?

GTx, Inc. (NASDAQ:GTXI) posted its quarterly earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.09. View GTX's Earnings History.

When is GTX's next earnings date?

GTX is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for GTX.

What price target have analysts set for GTXI?

2 brokers have issued 12 month target prices for GTX's shares. Their forecasts range from $17.00 to $45.00. On average, they expect GTX's stock price to reach $31.00 in the next twelve months. This suggests a possible upside of 3,183.9% from the stock's current price. View Analyst Price Targets for GTX.

What is the consensus analysts' recommendation for GTX?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GTX in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GTX.

Has GTX been receiving favorable news coverage?

Media stories about GTXI stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. GTX earned a news sentiment score of 1.4 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.

Who are some of GTX's key competitors?

Who are GTX's key executives?

GTX's management team includes the folowing people:
  • Dr. Robert James Wills Ph.D., Exec. Chairman (Age 65)
  • Mr. Marc S. Hanover, Co-Founder, CEO & Director (Age 56)
  • Mr. Henry P. Doggrell, VP, Chief Legal Officer & Sec. (Age 70)
  • Mr. Jason T. Shackelford, VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller (Age 44)
  • Dr. Diane C. Young, VP & Chief Medical Officer (Age 62)

Who are GTX's major shareholders?

GTX's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (1.93%), Geode Capital Management LLC (0.94%), Bank of America Corp DE (0.85%), Two Sigma Investments LP (0.55%), GSA Capital Partners LLP (0.45%) and Virtu Financial LLC (0.28%). Company insiders that own GTX stock include Diane C Young, Henry Patton Doggrell, Jason T Shackelford, Marc Steven Hanover and Robert James Wills. View Institutional Ownership Trends for GTX.

Which institutional investors are selling GTX stock?

GTXI stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC and BlackRock Inc.. Company insiders that have sold GTX company stock in the last year include Diane C Young, Henry Patton Doggrell and Jason T Shackelford. View Insider Buying and Selling for GTX.

Which institutional investors are buying GTX stock?

GTXI stock was purchased by a variety of institutional investors in the last quarter, including Bank of America Corp DE, GSA Capital Partners LLP, Virtu Financial LLC, Two Sigma Advisers LP and Two Sigma Investments LP. View Insider Buying and Selling for GTX.

How do I buy shares of GTX?

Shares of GTXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GTX's stock price today?

One share of GTXI stock can currently be purchased for approximately $0.9440.

How big of a company is GTX?

GTX has a market capitalization of $22.71 million. The biopharmaceutical company earns $-30,430,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. GTX employs 27 workers across the globe.

What is GTX's official website?

The official website for GTX is http://www.gtxinc.com.

How can I contact GTX?

GTX's mailing address is 175 TOYOTA PLAZA 7TH FLOOR, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected]


MarketBeat Community Rating for GTX (NASDAQ GTXI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  213 (Vote Outperform)
Underperform Votes:  174 (Vote Underperform)
Total Votes:  387
MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote "Outperform" if you believe GTXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel